Raynovent Biotech

Guangdong Raynovent Biotech is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the development of innovative small molecule and peptide drugs for respiratory and metabolic diseases. Established in 2018 as a subsidiary of Guangdong Zhongsheng Pharmaceutical, the company has rapidly advanced its pipeline, achieving regulatory approvals in China for Leritrelvir (RAY1216), a 3CL protease inhibitor for COVID-19, and Onradivir (ZSP1273), a first-in-class PB2 inhibitor for influenza A. Raynovent's diverse portfolio also includes RAY1225, a GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity and diabetes, and several candidates for non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company leverages its expertise in protease and kinase inhibition to address significant unmet medical needs in viral infections and chronic fibrotic diseases.